Tremelimumab is another anti-CTLA-4 inhibitor that is currently under investigation in clinical trials for various cancers, e.g., melanoma, malignant pleural mesothelioma, SCLC, and NSCLC [17,53]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.